We demonstrate that combination treatment with HER2 targeting monoclonal antibodies, Pertuzumab and Trastuzumab, causes inhibition of NRF2 function and subsequent repression of NRF2 dependent antioxidant response pathway in human ovarian cancer cell lines. Here, ERBB2 is linked to ovarian carcinoma.